The Indian Professional's Evidence-Based Guide to Choosing Supplements

A Growing Market With a Persistent Evidence Problem

India’s health supplement market has grown from a niche category to a mainstream consumer industry in less than a decade. Market estimates place the current size at ₹30,000 crore or more, growing at approximately 20% annually — driven by rising health consciousness among urban professionals, the post-2020 immunity-supplement boom, and the increasing normalisation of daily supplement use as part of a professional wellness routine.

The growth of the market has not been matched by a corresponding improvement in average product quality or evidence standards. For every supplement brand applying rigorous ingredient disclosure and clinical evidence to its formulation decisions, there are dozens using traditional Ayurvedic branding, vague wellness claims, and hidden ingredient doses to appeal to a consumer who wants to make evidence-informed choices but lacks the framework to evaluate what they are actually buying.

The evidence problem in Indian supplements operates at multiple levels: products with undisclosed ingredient doses, clinical claims based on in vitro evidence that has not translated to human trials, traditional use invocations presented as clinical validation, and proprietary blends that make independent dose verification impossible. This guide provides a practical framework for evaluating any supplement applied to the Indian market context.

The Four Evaluation Criteria

Criterion 1: Transparent Ingredient Disclosure — No Proprietary Blends

The minimum requirement for any supplement is a complete list of every active ingredient with its individual dose clearly declared. If a product lists a “proprietary blend,” “herbal complex,” or “cognitive support matrix” with a total weight but no individual ingredient breakdown, it has failed the first and most fundamental transparency test.

This matters because dose is the difference between a clinically relevant intervention and a label decoration. Brahmi has RCT evidence for memory improvements at 300mg per day. Ashwagandha has cortisol reduction evidence at 300mg of high-concentration root extract. If a product contains 5mg of Brahmi within a 500mg proprietary blend, the Brahmi on the label is present for marketing legitimacy rather than biological effect. Without individual dose disclosure, this cannot be detected by any means available to the consumer.

Criterion 2: Clinical Evidence — RCTs, Not Just In Vitro

The hierarchy of evidence in supplement research runs from weakest to strongest: in vitro (cell culture studies), animal studies, observational human studies, open-label human trials, and randomised double-blind placebo-controlled trials (RCTs). Marketing copy in the supplement industry frequently invokes evidence without specifying where in this hierarchy the cited research sits.

In vitro evidence means that a compound showed a particular effect in cultured cells in a laboratory dish. This is a useful first step in identifying potentially active compounds, but it does not predict human clinical effects. Most compounds that show interesting effects in vitro fail when tested in living organisms, and even more fail when tested in controlled human trials.

RCTs — randomised, double-blind, placebo-controlled trials in relevant human populations — represent the gold standard. Brahmi has multiple published RCTs in humans. Ashwagandha has multiple published RCTs in humans. Red Korean Ginseng has published RCT evidence in humans. These are not the same category of evidence as “studies show that ashwagandha may support stress” — the latter is often a reference to in vitro or rodent research dressed in hedged language.

Criterion 3: Regulatory Registration — FSSAI as the Minimum Bar

FSSAI (Food Safety and Standards Authority of India) registration is the regulatory minimum for any food supplement legally sold in India. FSSAI-registered products must declare all ingredients, cannot use prohibited substances, and must be manufactured under food-grade hygiene standards.

What FSSAI registration does not mean: efficacy validation. A supplement can be FSSAI-registered and still contain undisclosed doses (via proprietary blend labelling), still make claims supported only by in vitro evidence, and still be entirely ineffective for the conditions it implies it addresses. FSSAI registration is necessary but not sufficient — it eliminates the category of completely unregulated products but does not guarantee clinical effectiveness.

Criterion 4: Dose Relevance — Does It Match What Studies Used?

The fourth criterion is technically the most demanding but conceptually simple: the dose of an active ingredient in a supplement should correspond to the doses used in the clinical research that supports the product’s claims.

Brahmi (Bacopa monnieri): Stough et al. (2001) used 300mg of standardised Bacopa extract. Morgan and Stevens (2010) used 300mg. A product containing 50mg of Brahmi in a proprietary blend is not delivering a dose consistent with the evidence.

Ashwagandha (Withania somnifera): Chandrasekhar et al. (2012) used 300mg of high-concentration root extract (standardised to 5% withanolides).

Red Korean Ginseng (Panax ginseng): The 2022 RCT (PMC9270647) used 500mg of Panax ginseng extract — the dose present in All Day Energy by foryoudaily.

Sea Buckthorn (Hippophae rhamnoides): Research on skin hydration effects has typically used 500mg of Sea Buckthorn oil or extract — the dose present in Skin Hydration by foryoudaily.

How to Read a Supplement Label: An India-Specific Guide

What a Compliant, Transparent Label Shows

A well-formulated, evidence-aligned supplement label discloses: the product name and category, FSSAI registration number, a complete ingredient list with every active named individually and its dose stated in milligrams or micrograms, the serving size corresponding to the stated doses, any relevant standardisation information for extracts, manufacturer contact details, and a clear use-by date.

Red Flags to Identify Immediately

Proprietary blend labelling — any blended ingredient list with a total weight but no individual doses — is the primary red flag. “Blend” language in any form (“herbal matrix,” “cognitive complex,” “energy blend”) should trigger the question: where are the individual doses?

Vague evidence language — “studies suggest,” “traditional use supports,” “may help with” — is frequently used to invoke a clinical evidence impression without citing specific studies.

Missing FSSAI registration number is an immediate concern. Products sold in India without FSSAI registration are operating outside the regulatory framework entirely.

The Three Categories of Evidence

Category 1: Traditional Use Only

Many herbs and botanical ingredients have long traditional use histories without any modern mechanistic characterisation or clinical trial validation. Traditional use is not worthless evidence. But it does not establish mechanism, dose-response relationships, safety in vulnerable populations, or the comparative effect size versus placebo that an RCT provides. “Used in Ayurveda for thousands of years” is a historical fact; “clinically proven to improve cognitive function” requires human RCT data.

Category 2: Traditional Use + Mechanistic Evidence

The second category includes herbs with both traditional use classification and modern mechanistic research — typically in vitro or animal studies — that have characterised the biological pathways through which the herb may produce its effects. This is meaningfully stronger than traditional use alone but does not constitute proof that the herb produces the claimed effect at a relevant dose in a human population.

Category 3: Traditional Use + Mechanistic Evidence + Human RCTs

The third category — and the strongest evidence base available — combines traditional classification, mechanistic characterisation, and human RCT evidence. For cognitive and wellness supplements in the Indian market, the herbs in Category 3 are Brahmi (Bacopa monnieri) for memory and working memory, Ashwagandha (Withania somnifera) for stress and cortisol reduction, and Red Korean Ginseng (Panax ginseng) for fatigue reduction.

Applied to foryoudaily: How the Framework Evaluates Our Products

Daily Focus: The Cognitive Formulation

Ingredient transparency: All 8 actives are individually named and disclosed — Shankhpushpi, Brahmi Extract, Bringaraj Extract, Vach Extract, Ashwagandha Extract, Shatavari Extract, Malkangni Extract, and Amaltas Extract. No proprietary blend.

Clinical evidence: Brahmi and Ashwagandha are in Category 3. Brahmi: Stough et al. (2001) and Morgan and Stevens (2010) both found statistically significant cognitive improvements in RCTs; meta-analysis PMC2915594 found 55% of participants showed 21%+ memory improvements. Ashwagandha: Chandrasekhar et al. (2012, PMID 23439798) found a 27.9% serum cortisol reduction.

Regulatory status: FSSAI registered. Dose relevance: Doses correspond to the range used in published clinical research for the primary evidence-bearing ingredients.

All Day Energy: The Ginseng Formulation

Ingredient transparency: One ingredient — Red Korean Ginseng Extract 500mg — named, dosed, and disclosed. No blend of any kind.

Clinical evidence: Panax ginseng is in Category 3 for fatigue. PMC9270647 (2022 RCT) found statistically significant reductions in blood lactate and creatine kinase in fatigued adults.

Regulatory status: FSSAI registered. Dose relevance: 500mg matches the dose used in the primary fatigue RCT evidence.

Skin Hydration: The Sea Buckthorn Formulation

Ingredient transparency: Sea Buckthorn Extract 500mg — named, dosed, and disclosed. Single active ingredient.

Clinical evidence: Sea Buckthorn sits between Category 2 and Category 3 for skin hydration. Mechanistic evidence is strong — omega-7 fatty acids (palmitoleic acid) are a component of the skin’s natural lipid barrier. Yang et al. (Journal of Applied Cosmetology, 2009) studied sea buckthorn oil in female subjects using both oral supplementation and topical application, and reported improvements in skin moisture content and barrier function.

Regulatory status: FSSAI registered. Dose relevance: 500mg corresponds to the dose range used in skin hydration research.

Common Marketing Claims That Lack Clinical Support

“Boosts immunity instantly” — The immune system does not respond to most botanical interventions on the timescale of hours or days. Claims of instant immune support for botanical supplements have no credible clinical basis.

“Detoxifies the body” — The liver and kidneys are the body’s detoxification systems. “Detox” as a category of claim is not meaningfully defined in either Ayurvedic or modern clinical terms and serves primarily as marketing vocabulary.

“Clinically proven” (with no citation) — If a product claims clinical proof, the study should be citable — journal, year, and PMID or PMC number. If it is not citable, it is a marketing claim, not an evidence claim.

Before-and-after testimonials as evidence — Individual testimonials are not clinical evidence for any supplement. They cannot account for placebo effects, natural variation in individual response, or the many confounding factors that influence how someone feels over 4–12 weeks.

Frequently Asked Questions

How do I evaluate supplement quality in India?

Apply four criteria in sequence. First, check ingredient transparency: every active ingredient should be individually named with its dose disclosed — proprietary blend labelling is a disqualifying red flag. Second, assess evidence quality: distinguish in vitro studies (weakest) from animal studies from human RCTs (strongest). Third, verify dose relevance: does the product dose correspond to doses used in RCTs? A Brahmi product containing 50mg is not delivering the 300mg dose where clinical effects have been demonstrated. Fourth, confirm FSSAI registration. Products passing all four criteria represent a small minority of the Indian supplement market.

What is FSSAI registration and why does it matter?

FSSAI (Food Safety and Standards Authority of India) is the central food and supplement regulatory body under the Food Safety and Standards Act, 2006. FSSAI registration confirms compliance with safety standards, labelling requirements, permitted ingredient lists, and manufacturing hygiene regulations. It is the minimum regulatory bar — an unregistered supplement has no regulatory oversight of any kind. However, FSSAI registration does not validate clinical efficacy claims. FSSAI registration is necessary but not sufficient.

Are Ayurvedic supplements regulated in India?

Ayurvedic products in India fall under two parallel regulatory frameworks. Products classified as Ayurvedic medicines fall under the Drugs and Cosmetics Act, 1940, regulated by the Ministry of AYUSH. Products classified as food supplements or nutraceuticals fall under FSSAI regulation and cannot make specific disease treatment claims. Many consumer Ayurvedic supplements are FSSAI-registered food supplements — a transparent and appropriate classification. The regulatory classification should be visible on the label.

What is a proprietary blend and why should I avoid it?

A proprietary blend discloses the total weight of a blend of ingredients without revealing the individual dose of each ingredient within that blend. This practice makes dose validation impossible. It also creates the incentive for manufacturers to use more of the cheaper ingredients and less of the expensive, clinically evidenced ones. Full individual dose disclosure for every active ingredient is the only basis on which you can verify whether a supplement contains doses consistent with its evidence base.

How long should I take a supplement before expecting results?

The appropriate evaluation window depends on the supplement category and mechanism. HPA axis modulation (Ashwagandha for cortisol reduction): measurable effects in clinical studies at 4–8 weeks. Cognitive improvements (Brahmi for memory and working memory): RCT evidence typically at 8–12 weeks. Fatigue biomarker reduction (Red Korean Ginseng): 4–8 weeks in clinical studies. Skin hydration (Sea Buckthorn): 8–12 weeks for consistent barrier function improvement. The consistent principle: these supplements address biological systems that were degraded over months or years — restoration is gradual. Evaluating effectiveness after 1–2 weeks means assessing the supplement before its mechanism has had time to operate.

Disclaimer: This product is not intended to diagnose, treat, cure, or prevent any disease. The information in this article is for educational purposes only and is not a substitute for professional medical advice. foryoudaily products are food supplements registered with FSSAI. Individual results may vary. Consult a qualified healthcare professional before starting any new supplement regimen, especially if you are pregnant, breastfeeding, or managing a medical condition.